SAN FRANCISCO (GenomeWeb) – New guidelines from the American College of Obstetrics and Gynecology on the use of noninvasive prenatal testing in average-risk pregnancies have not yet come out, but Natera continues to anticipate that the guidelines will be favorable and encourage the holdouts in the payor community to cover testing. With 60 percent of its noninvasive prenatal tests going into that market, broader reimbursement would be a big boon for the company.

In the meantime, however, the firm is making progress in the other areas of its business: oncology and transplantation.